Physician profile
Susan E Shamburger
NPI 1891863502
$3,399.69
in general payments reported to CMS, 2019-2025
14 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $62.71 · 2021: $52.52 · 2022: $131 · 2023: $64.72 · 2024: $2,483 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $387.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $2,569.58 | 2019-2024 | Brevera Breast Biopsy System |
| Medtronic USA, INC. | $129.89 | 2019 | |
| Hologic Sales and Service, LLC | $126.13 | 2023-2025 | Brevera Breast Biopsy System, Atec, Localizer |
| Puma Biotechnology, INC. | $122.58 | 2019-2024 | |
| Medtronic, INC. | $120.08 | 2025 | Kyphon Express II Kyphopak Tray |
| Leica Microsystems INC. | $118.80 | 2022 | |
| Amgen INC. | $98.13 | 2019-2020 | |
| Conmed Corporation | $20.76 | 2024 | Airseal |
| Foundation Medicine, INC. | $18.29 | 2021 | |
| Shield Therapeutics INC | $18.16 | 2024 | |
| Focal Therapeutics, INC. | $17.53 | 2020 | |
| Lilly USA, LLC | $14.55 | 2025 | Zepbound |
| Mayne Pharma Commercial LLC | $13.90 | 2025 | |
| Novartis Pharmaceuticals Corporation | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Shamburger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.